Navigation Links
Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
Date:10/18/2010

BRANFORD, Conn., Oct. 18 /PRNewswire/ -- HistoRx announced that Heiner Dreismann, Ph.D. has accepted its invitation to join the Board of Directors.  As the former President and CEO of Roche Molecular Systems, Dr. Dreismann is an acknowledged diagnostic industry expert.

Dr. Dreismann was with Hoffmann La Roche for twenty years serving in several roles, including Head of Global Business Development Roche Diagnostics, Head of PCR Business Unit for Europe, President and CEO of Roche Molecular Systems and member of the global Executive Committee of Roche Diagnostics.  HistoRx CEO Rana K. Gupta approached Dr. Dreismann with the opportunity, commenting, "As we reach the commercialization stage of our diagnostics portfolio it's important to add knowledgeable experts from the global distribution companies that have brought new technologies forward to labs around the world.  Heiner's experience with the launch and market development of PCR, and his familiarity with key decision makers across the diagnostics industry make him a valuable addition to the HistoRx Board."

"I am pleased to join the board of directors of HistoRx, a company that has developed a unique and innovative technology to address the key unmet need of the pathology community," Dreismann stated. "HistoRx products have great potential in the United States and overseas markets."

About HistoRx (www.historx.com)

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  For more information please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
2. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
3. American Humane Association Announces Joy Mench, Ph.D., Joins the Scientific Advisory Committee of the American Humane Certified® Farm Animal Program
4. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
5. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
6. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. 5th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Peter K. Vogt, Ph.D., The Scripps Research Institute
9. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
10. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
11. Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
(Date:2/16/2017)... Indiana (PRWEB) , ... February ... ... of Albany Molecular Research Inc. has further extended its industry leading Biochemistry ... This service offers state-of-the-art cGMP techniques and methods for the biochemical ...
(Date:2/15/2017)... Clara, CA (PRWEB) , ... February 15, 2017 , ... ... announced that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with ... SmartScan completely automatizes all of the functions of setting up and taking the image ...
(Date:2/15/2017)... WASHINGTON , Feb. 15, 2017  NASA provider ... Services mission to the  International Space Station  no earlier ... of the launch will begin at 8:30 a.m. on ... SpaceX Dragon spacecraft will lift off on ... at NASA,s Kennedy Space Center ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
Breaking Biology News(10 mins):